C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. ACN
10. USO

Go back to C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Credit Suisse Upgrades C4 Therapeutics (CCCC) to Neutral, 'Improved Outlook w/ Multiple Shots on Goal Post 4Q22 EPS'

February 24, 2023 1:24 PM EST

Credit Suisse analyst Richard Law upgraded C4 Therapeutics (NASDAQ: CCCC) from Underperform to Neutral with a price target of $10.00 (from $12.00).

The analyst comments "CCCC reported 4Q22 financial results on Thursday morning with GAAP EPS of -$0.65. Total collaboration revenues... More